LAKE FOREST, Ill., Sept. 30 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the U.S. Food and Drug Administration's approval of its 10 mg/mL strength of Ketamine Hydrochloride Injection, USP, the generic equivalent of JHP Pharmaceuticals' Ketalar(R)CIII.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)
The 10 mg/mL strength joins Bioniche's current offering of Ketamine in 50 mg/mL and 100 mg/mL strengths and completes its full product line offering. Bioniche plans to launch the 10 mg/mL strength in October.
"We are pleased to offer our customers a full line of Ketamine for their treatment needs," said Steve Thornton, CEO Bioniche Pharma.
About Bioniche Pharma:
Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at http://www.bionichepharma.com.
CONTACT: Kara Maxwell of Bioniche Pharma, +1-847-739-3249,
kmaxwell@bionichepharmausa.com
Web site: http://www.bionichepharma.com/
